{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:14:37Z","timestamp":1788347677022,"version":"build-2803163510"},"reference-count":24,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Annals of Gastroent Surgery"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant chemotherapy with fluorouracil, cisplatin, and docetaxel (NAC\u2010DCF) followed by surgery is the current standard of care for resectable advanced esophageal squamous cell cancer (ESCC) in Japan based on the JCOG1109 trial. Although NAC\u2010DCF improves survival, it also increases the risk of febrile neutropenia. Therefore, it is essential to identify tumor factors that predict the greatest benefit from NAC\u2010DCF over conventional fluorouracil and cisplatin chemotherapy (NAC\u2010CF) to optimize patient selection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed patients with resectable advanced ESCC who received either NAC\u2010CF or NAC\u2010DCF at our institution between 2006 and 2019. Propensity score\u2010based inverse probability weighting (IPW) and multivariable adjusted analyses were used to consider baseline differences and compare overall survival (OS) stratified by cTNM factors between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 408 patients received NAC\u2010CF, while 218 received NAC\u2010DCF. NAC\u2010DCF was applied to more advanced patients, with 86% having cT3\u20104a and 52% having cN2\u20103 (both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). After IPW, the hazard ratio (HR) for OS in the NAC\u2010DCF group was 0.74 [95% confidence interval (CI), 0.55\u20130.98]. Subgroup analysis showed that patients with cN2\u20103 had a significant survival benefit with NAC\u2010DCF (HR 0.51; 95% CI, 0.34\u20130.76) in the IPW analysis, whereas no clear association was observed in those with cN0\u20131 (HR 0.93; 95% CI, 0.62\u20131.34), with a nominally significant interaction by clinical N stage (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.039).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Neoadjuvant chemotherapy with fluorouracil, cisplatin, and docetaxel (NAC\u2010DCF) was associated with improved survival, with a potential benefit in patients with advanced nodal involvement; however, these findings should be interpreted as hypothesis\u2010generating given the retrospective design.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ags3.70224","type":"journal-article","created":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T23:00:16Z","timestamp":1776639616000},"page":"1496-1506","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential Survival Benefit of Neoadjuvant Docetaxel, Cisplatin and 5\u2010Fluorouracil Therapy in Patients With Esophageal Squamous Cell Carcinoma With Multiple Lymph Node Metastases: A Single\u2010Institute Propensity Score Analysis"],"prefix":"10.1002","volume":"10","author":[{"given":"Eiji","family":"Higaki","sequence":"first","affiliation":[{"name":"Department of Gastroenterological Surgery Aichi Cancer Center Hospital  Nagoya Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery Aichi Cancer Center Hospital  Nagoya Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Fujieda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery Aichi Cancer Center Hospital  Nagoya Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenori","family":"Kadowaki","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Aichi Cancer Center Hospital  Nagoya Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Endoscopy Aichi Cancer Center Hospital  Nagoya Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3761-6971","authenticated-orcid":false,"given":"Masahiro","family":"Tajika","sequence":"additional","affiliation":[{"name":"Department of Endoscopy Aichi Cancer Center Hospital  Nagoya Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6834-995X","authenticated-orcid":false,"given":"Koji","family":"Komori","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery Aichi Cancer Center Hospital  Nagoya Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery Aichi Cancer Center Hospital  Nagoya Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Oze","sequence":"additional","affiliation":[{"name":"Division of Cancer Information and Control Aichi Cancer Center Research Institute  Nagoya Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Muro","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Aichi Cancer Center Hospital  Nagoya Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,19]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.003"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0019"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(23)00243\u20101"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409408"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434\u2010011\u20102049\u20109"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(24)00745\u20101"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434\u2010020\u201008865\u20100"},{"issue":"10","key":"e_1_2_11_9_1","first-page":"3535","article-title":"Docetaxel Plus 5\u2010Fluorouracil and Cisplatin (DCF) Induction Chemotherapy for Locally Advanced Borderline\u2010Resectable\u00a0T4 Esophageal Cancer","volume":"31","author":"Yokota T.","year":"2011","journal-title":"Anticancer Research"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000005533"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010015\u20102806\u20108"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00595\u2010020\u201002001\u2010x"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000001828"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.350"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyz112"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434\u2010023\u201014779\u20104"},{"issue":"4","key":"e_1_2_11_17_1","first-page":"1403","article-title":"Phase II Study of Docetaxel, Cisplatin and 5\u2010Fluorouracil (DCF) for Metastatic Esophageal Cancer (OGSG 0403)","volume":"32","author":"Tamura S.","year":"2012","journal-title":"Anticancer Research"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112088"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03614"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacr.2022.09.008"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20190827"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00330\u2010024\u201011234\u20100"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010025\u201007603\u20106"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e14030"}],"container-title":["Annals of Gastroenterological Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ags3.70224","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ags3.70224","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ags3.70224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:30:07Z","timestamp":1788345007000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ags3.70224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,19]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/ags3.70224"],"URL":"https:\/\/doi.org\/10.1002\/ags3.70224","archive":["Portico"],"relation":{},"ISSN":["2475-0328","2475-0328"],"issn-type":[{"value":"2475-0328","type":"print"},{"value":"2475-0328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,19]]},"assertion":[{"value":"2026-01-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}